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Sex chromosome trisomies in Europe: prevalence,
prenatal detection and outcome of pregnancy
Patricia Anne Boyd*,1, Maria Loane2, Ester Garne3, Babak Khoshnood4,5 and Helen Dolk2, a EUROCAT
working group6
This study aims to assess prevalence and pregnancy outcome for sex chromosome trisomies (SCTs) diagnosed prenatally or in
the first year of life. Data held by the European Surveillance of Congenital Anomalies (EUROCAT) database on SCT cases
delivered 2000–2005 from 19 population-based registries in 11 European countries covering 2.5 million births were analysed.
Cases included were livebirths diagnosed to 1 year of age, fetal deaths from 20 weeks gestation and terminations of pregnancy
for fetal anomaly (TOPFA). In all, 465 cases of SCT were diagnosed between 2000 and 2005, a prevalence of 1.88 per 10,000
births (95% CI 1.71–2.06). Prevalence of XXX, XXY and XYY were 0.54 (95% CI 0.46–0.64), 1.04 (95% CI 0.92–1.17) and
0.30 (95% CI 0.24–0.38), respectively. In all, 415 (89%) were prenatally diagnosed and 151 (36%) of these resulted in
TOPFA. There was wide country variation in prevalence (0.19–5.36 per 1000), proportion prenatally diagnosed (50–100%)
and proportion of prenatally diagnosed resulting in TOPFA (13–67%). Prevalence of prenatally diagnosed cases was higher in
countries with high prenatal detection rates of Down syndrome. The EUROCAT prevalence rate for SCTs diagnosed prenatally or
up to 1 year of age represents 12% of the prevalence expected from cytogenetic studies of newborn babies, as the majority of
cases are never diagnosed or are diagnosed later in life. There is a wide variation between European countries in prevalence,
prenatal detection and TOPFA proportions, related to differences in screening policies as well as organizational and cultural
factors.
European Journal of Human Genetics (2011) 19, 231–234; doi:10.1038/ejhg.2010.148; published online 25 August 2010
Keywords: sex chromosome trisomies; prenatal diagnosis; termination of pregnancy
INTRODUCTION
Sex chromosome trisomies (SCTs; an extra X chromosome in females
(triple X, XXX), males with an extra X chromosome, (Klinefelter
syndrome, XXY) and males with an extra Y chromosome (XYY)),
occur after an error during meiosis of the X or Y chromosome.
Cytogenetic surveys of newborn infants carried out in the 1970’s
established incidence figures for each of the SCTs at around 1 in 1000
same sex individuals.1–3 A recent study reported that the prevalence of
Klinefelter’s syndrome is increasing.4
In contrast to the effect of an extra autosome, the effect of an extra
sex chromosome is usually mild and most of the individuals born with
one never get diagnosed.5,6 SCTs together represent the most common
chromosome abnormalities compatible with live birth, a usually
normal lifespan and few, if any dysmorphic features. Although
major physical anomalies are not associated with SCTs, men with
XXY are infertile. The relatively small amount of information available
from population-based studies indicate that individuals with SCT are
at increased risk of educational failure and neurodevelopmental
disorder, with mean IQ broadly within the normal limits but reduced
10–20 points when compared with siblings; the biggest reduction in
IQ being associated with XXX females.5,7–10
Some SCT cases are identified by chance prenatally when karyotyp-
ing is performed for different reasons,11 for example, after a higher
risk Down’s syndrome screening test. Parents are then faced with the
knowledge that their baby has a condition about which there is a lack
of information available from unbiased studies. After prenatal detec-
tion, parents receive information about the specific SCT from a variety
of professionals and other sources. Some of the information given may
be outdated, inaccurate and unduly negative because of the ascertain-
ment bias inherent in small select populations in the studies of affected
children.7–9,11–13 Termination of pregnancy for fetal anomaly
(TOPFA) is requested by some parents after prenatal diagnosis of a
SCT. Rates of prenatal detection, information given to parents and
differences in laws and practices regarding termination of pregnancy
are some factors which may lead to differences in outcome.11–16
During the last decade, in many countries, there has been a move
from offering only older mothers karyotyping to check for Down’s
syndrome, to offering all mothers first or second trimester screening
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tests.16 Given the known association of XXX and XXY with maternal
age,17 there may be a change in the prenatal detection rate of SCTs.
The European Surveillance of Congenital Anomalies (EUROCAT) is
a network of population-based congenital anomaly registers in Europe
which surveys more than 1.5 million births per year, and covers 29%
of the annual European birth population.18 Full member registries of
EUROCAT send anonymous case data on congenital anomalies
including information on TOPFA in their region. One of the objec-
tives of EUROCAT is to assess the impact of prenatal screening.
The aim of this paper is to provide a snapshot view of the
occurrence of SCTs in Europe during the 6 years, 2000–2005 to enable
monitoring of their prenatal detection and outcome of pregnancy
as prenatal screening practices evolve. The specific objectives are
to report the total prevalence of SCTs diagnosed up to 1 year of age
in Europe; to describe the prevalence and proportion of prenatally
diagnosed cases, gestational age (GA) at prenatal diagnosis and out-
come of pregnancy of prenatally diagnosed cases and finally to relate
the prevalence of prenatally diagnosed cases to the extent of prenatal
karyotyping in the country (as indicated by the proportion of Down’s
syndrome cases detected prenatally, by maternal age).
METHODS
EUROCAT registries with GA at detection of a malformation known for at least
80% of SCTs for cases delivered between 2000 and 2005 were invited to
participate in the study. Cases including livebirths, fetal deaths from 20 weeks
gestation and those resulting in TOPFA after the prenatal diagnosis with a
47,XXX, 47,XXY or 47,XYY karyotype and date of delivery or TOPFA from
2000 to 2005 inclusive, were extracted from the EUROCAT database. SCT cases
diagnosed after 1 year of age or those with a mosaic karyotype were excluded.
The upper age limit for reporting cases of congenital anomaly at registry
level is at least 1 year of age and 15 of the 19 participating registries complied
with this. Four registries (Barcelona, Emilia Romagna, Paris and South
Portugal) limit postnatal registration to 3 days, 1 week, 1 week and 1 month,
respectively.
The observed EUROCAT prevalence of SCTs was calculated and compared
with that expected. Expected prevalence rates (5.0 per 10 000 births for XXX
and XYY and 6.3 for XXY) were obtained from published cytogenetic studies
of consecutive newborns in the 1970s.1–3 Information on prenatal detection
rates for Down’s syndrome cases was extracted for the same registries and time
period (2000–2005) to give a measure of the extent of prenatal karyotyping.
Variation in prevalence between countries was assessed using a w2 test
(STATA version 9.0, StataCorp LP, College Station, TX, USA).
RESULTS
In all, 19 EUROCAT Registries from 11 European countries agreed to
take part in the study and fulfilled the entry criteria. There were
approximately 2.5 million births in the registry areas (10% of total
births in the 11 countries) during the 6-year study period (Table 1) of
which 465 were diagnosed as having a SCT before the age of 1 year.
The overall prevalence of SCT was 1.88 per 10 000 births (95% CI
1.71–2.06), ranging from 0.19 (95% CI 0.07–0.52) in Poland to 5.36
(95% CI 3.57–8.07) in Switzerland (Table 1). A w2 for heterogeneity
test showed highly significant variation in prevalence of SCT between
countries (Po0.001).
A total of 415 cases (89%) were diagnosed prenatally at a median
gestation of 16 weeks, of which 151 (36%) resulted in TOPFA (Table 1).
The median GA at prenatal diagnosis varied between countries from 11
weeks in Denmark to 21 weeks in Poland (Table 1). There was significant
variation in the proportion of prenatally diagnosed SCTs resulting in
TOPFA between countries (Po0.001).
Figure 1 shows the observed EUROCAT and expected prevalence1–3
of the three SCTs. The EUROCAT prevalence of XXX was 0.54 per
10 000 births (95% CI 0.46–0.64), of XXY was 1.04 per 10 000 births
(95% CI 0.92–1.17) and of XYY was 0.30 per 10 000 births (95% CI
0.24–0.38). Overall, the EUROCAT prevalence of all SCTs combined
represented 12% of the prevalence expected from cytogenetic studies
of newborn babies. XXY had the highest EUROCAT or expected
prevalence ratio (1.0: 6.3 per 10 000 births), representing 17% of the
expected prevalence.
Figure 2 shows the percentage of cases prenatally diagnosed and the
percentage of prenatally diagnosed cases resulting in TOPFA for each SCT.
Overall, 41% of all SCTs prenatally diagnosed in motherso35 years
were terminated, though the proportion varied by type of SCT (50%
of XXX, 40% of XXY and 32% of XYY). In contrast, 33% of all SCTs
prenatally diagnosed in mothers Z35 yearswere terminated (23% of
Table 1 Total number of births in EUROCAT registry areas in 2000–2005; number and prevalence of sex chromosomal trisomy cases,
percentage prenatally diagnosed, median gestational age at diagnosis and percentage of prenatally diagnosed cases resulting in
termination of pregnancy
Country EUROCAT register(s)
Number of births in
EUROCAT registry
areas 2000–2005
Total cases sex
chromosome
trisomy
Prevalence all sex
chromosomal trisomies
per 10 000 births
(95% confidence intervals)
%
Cases
PD
Median
GA at
diagnosis
% Cases of
PD ending
in TOPFA
Austria Styria 62667 8 1.28 (0.64–2.55) 100 15 13
Belgium Antwerp, Hainaut 182 467 38 2.08 (1.52–2.86) 79 16 27
Denmark Odense 32003 5 1.56 (0.65–3.75) 60 11 67
England and Wales E Mid and S York, Northern England,
Thames Valley, Wales, Wessex
951 001 121 1.27 (1.07–1.52) 79 16 27
France Paris, Strasbourg 272 618 84 3.08 (2.49–3.82) 98 17 38
Germany Saxony-Anhalt 106 257 18 1.69 (1.07–2.69) 78 15 43
Italy Emilia Romagna, Tuscany 343 971 92 2.67 (2.18–3.28) 97 16 46
Poland Wielkopolska 206 170 4 0.19 (0.07–0.52) 50 21 0
Portugal Southern Portugal 113 310 18 1.59 (1.00–2.52) 100 18 44
Spain Barcelona, Basque Country 164 864 54 3.28 (2.51–4.28) 95 16 44
Switzerland Vaud 42874 23 5.36 (3.57–8.07) 96 17 23
Total 2 478 202 465 1.88 (1.71–2.06) 89 16 36
Abbreviations: E Mid, East Midlands; EUROCAT, European Surveillance of Congenital Anomalies; GA, gestational age; PD, prenatal diagnosis; S York, South Yorkshire; TOPFA, termination of
pregnancy for fetal anomaly.
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XXX, 41% of XXY and 28% of XYY). The difference in proportion of
termination rates performed for SCTs in under and over 35-year old
mothers is statistically significance (P¼0.046).
Figure 3 shows the relationship between prevalence of prenatally
diagnosed SCTs and the extent of prenatal karyotyping in the country
(as indicated by the proportion of Down’s syndrome cases detected
prenatally), in mothers Z35 and those o35, 2000–2005. In 7 out of
10 countries included in this analysis, o60% of Down’s syndrome
cases in mothers o35 years were prenatally diagnosed. These seven
countries have a corresponding low prevalence of prenatally diagnosed
SCTs in mothers o35 years (o1 per 10 000 births). The three
countries with the highest prenatal detection rate for Down’s
syndrome in mothers aged o35 years (France, Spain and
Switzerland)) have a higher prevalence of SCT in this age group
(range 1.03–1.78 per 10 000 births). In Poland, where 4% of Down’s
syndrome cases were prenatally detected in mothers 35+ years, the
prevalence of SCTs among older mothers was 1.14 per 10 000. In all
countries except Poland, 460% of Down’s syndrome cases were
detected in mothers 35+ years, and prevalence of prenatally diagnosed
SCT ranged from 4.15 per 10 000 births to 17.67 per 10 000 births.
DISCUSSION
SCTs represent an important and often neglected group of anomalies.
It is well established that most individuals with SCTs never get
diagnosed and that many of those that do are due to chance rather
than because of a suspicion of the extra sex chromosome.6 The reason
for the high prenatal diagnosis rate for SCTs described in this study is
because only those diagnosed before 1 year of age are included and
most get diagnosed because of the prenatal karyotyping
performed because of advanced maternal age or as a result of a
Down’s syndrome screening test.
This study showed a prevalence of SCTs diagnosed prenatally or in
the first year of life of 1.88 per 10 000 birth, representing approxi-
mately 12% of the expected prevalence. The expected prevalence was
based on the studies of newborns infants carried out in the 1970s, in
which every newborn was karyotyped at the time of birth. Given that
currently there are a higher proportion of older mothers than in the
1970s, and the risk for XXX and XXY increases with maternal age,17
the expected prevalence given is probably an underestimate for our
population. It was not possible for us to estimate meaningful age-
specific prevalence, as the chances of prenatal detection varies by age.
Abramsky and Chapple6 studied numbers of XXY and XYY males
diagnosed pre- or postnatally during the 4 years between 1990 and
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Figure 2 Percentage of sex trisomy cases prenatally diagnosed and the
percentage of prenatally diagnosed cases resulting in termination of
pregnancy for fetal anomaly, for each sex chromosome anomaly. PD, prenatal
diagnosis.
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Figure 3 Relationship between prevalence of prenatally diagnosed sex
chromosome trisomies and proportion of Down’s syndrome cases detected
prenatally. The percentages below are the percentage of Down’s syndrome
cases prenatally diagnosed and the prevalences cited are the prevalence of
prenatally diagnosed sex chromosome trisomies per 10000 births. Mothers
o35 years: Austria 54%, 0.37; Belgium 52%, 0.53; Denmark 38%, 0.00;
France 80%, 1.03; Germany 60%, 0.74; Italy 56%, 0.98; Poland 4%, 0.00;
Spain 67%, 1.38; Switzerland 88%, 1.78; UK 48%, 0.33. Mothers 35+
years: Austria 73%, 6.79; Belgium 66%, 5.86; Denmark 87%, 6.05; France
94%, 8.84; Germany 83%, 6.07; Italy 85%, 7.04; Poland 4%, 1.14; Spain
88%, 5.57; Switzerland 94%, 17.67; UK 70%, 4.15. Analysis based on 17
out of 19 registries—Hainaut (Belgium) and South Portugal were excluded as
maternal age denominators available for o80% of the population.
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Figure 1 Observed and expected prevalence per 10 000 births for sex
chromosome trisomies, 2000–2005.
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1993, and compared them with the numbers expected from cytoge-
netic surveys. Regarding XXY males, they estimated that approxi-
mately 12% were diagnosed prenatally and a further 1% postnatally
under 1 year of age, none between 1 and 10 years, 7% between 11 and
20 years and 19% at more than 20 years – a total of 12% diagnosed
prenatally and 27% diagnosed postnatally. Regarding the XYY cases,
approximately 5% were diagnosed prenatally and 12% postnatally
(1% under 1 year, 5% between 1 and 20 years and 6% at more than 20
years). The higher percentage of XXY than XYY cases diagnosed
prenatally reflects the association with maternal age17 and postnatally
the associated infertility leading to karyotyping in the 420 age group.
This study shows a higher percentage of the expected cases being
diagnosed for XXY males (17% compared with 13% up to 1 year of
age), possibly because of an increase in prenatal karyotyping. As XYY
is not associated with maternal age, it is not surprising that both
studies report a low prenatal detection rate for this SCT.
We found that the proportion of the expected cases diagnosed was
higher for XXY than for XXX and XYY in the EUROCAT data. Given
that XXX is strongly related to the maternal age, XXY has some
relationship and XYY no relationship,17 that average maternal age has
gone up since the newborn cytogenetic surveys, and that the prenatal
karyotyping rate is greater among older mothers, we would have
predicted a higher proportion of expected cases for XXX rather than
XXY. Our contrary result may reflect a feature of XXY that increases the
chance for prenatal detection, or that the true prevalence has increased.4
The wide variation in observed prevalence, in the proportion of
cases prenatally diagnosed, and in the proportion of those that are
electively terminated found in this and other studies,19 reflects at least
in part, the variation across European registries in the availability of
prenatal screening (ultrasound and antenatal screening for Down’s
syndrome) as well as organizational and cultural factors.16 We found
that although prevalence of prenatally diagnosed SCTs was clearly
broadly related to the prenatal detection rate of Down Syndrome,
there was still considerable further variation. For example, Switzerland
had a particularly high rate of prenatally diagnosed SCTs among older
mothers. This may reflect variation between countries in the extent to
which amniocentesis and CVS are preceded by screening tests in older
mothers, which reduce the rate of invasive tests in this age group.
Although the majority of SCTs detected prenatally would be because
of the karyotyping performed because of advanced maternal age or a
higher risk Down’s syndrome screening test, some may have been
because of suspicion of abnormality on prenatal ultrasound scan and
details of these scans are not available in our study.
This study provides baseline data on prenatal detection and
prevalence rates of SCTs, which will enable the monitoring of changes
in screening practices, affecting the detection of SCTs. The increasing
use of screening tests for Down’s syndrome such as the first trimester
combined test, offered to women of any age, to identify those at high
risk has led to a reduction in the diagnostic test rate in some centres20
and this is likely to be reflected in a lower detection rate of SCTs in the
future. The introduction of noninvasive prenatal diagnosis in the
future21 means that it would be feasible to test for SCTs in all
pregnancies. Whether SCTs should be included or excluded in the
diagnostic tests performed and what the advantages and disadvantages
would be are complex and controversial.
This study found that 36% of prenatally diagnosed SCTs result in
TOPFA. A declining trend in TOPFA for SCTs has been reported.12–15
Whether this reflects more positive counseling from health profe-
ssionals or a better understanding of the sex chromosome condition is
not known. The significantly higher termination rate for XXX cases in
mothers aged o35 compared with those 435 years in this study is
difficult to explain. Whether there is an advantage in diagnosing SCTs
prenatally when the aim of the prenatal screening test is to detect
Down’s syndrome is debatable. Parents are faced with difficult
information and decisions. For those that continue the pregnancy
forewarning of potential learning and behavioral difficulties10 may
allow early intervention and support.
The importance of providing parents with accurate information about
the frequency of the diagnosis and the variability of the condition on the
basis of outcomes from unbiased population-based follow-up studies on
the specific chromosome abnormality cannot be over emphasized.5
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